Skip to content
MRI Prostate

Prostate158

Prostate158 expert-annotated biparametric 3T prostate MRI dataset

Prostate MRI of men with suspected cancer, with expert segmentations of the prostate zones and suspicious lesions, a public benchmark for prostate anatomy and cancer segmentation. 158 men from Charité Berlin, split into 139 training and 19 test cases.

Overview

Prostate158 is a public benchmark for segmenting prostate anatomy and suspected cancer on biparametric MRI. Radiologists at Charité - Universitätsmedizin Berlin assembled it together with collaborators from Radboud University Medical Center, and released it with baseline U-Net models and training code.

Composition

The collection holds 158 examinations of men with suspected prostate cancer: 139 for training and 19 for testing. Cancer was confirmed by histology in 102 patients (83 training, 19 test); the other 56 served as controls. Every case has an axial T2-weighted image, a high b-value diffusion image and an ADC map. The data descriptor reports a mean age of 69 years (SD 9, range 35 to 84), PI-RADS 4 in 55 and PI-RADS 5 in 47 patients, and Gleason grade groups 1 to 5 in 11, 37, 24, 21 and 9 patients. The training archive ships train.csv and valid.csv that split it further.

Acquisition

Patients were scanned between February 2016 and January 2020 on two Siemens 3 T systems (VIDA and Skyra) with a protocol following PI-RADS v2.1. T2w images have 3 mm slices with 0.47 mm in-plane resolution. DWI used b-values up to 1000 s/mm², and the scanner software computed the ADC map. Only the b = 1000 image was kept. All sequences were resampled onto the T2w grid, center-cropped by removing 25% of the margins, N4-corrected (T2w) and stored as NIfTI.

Annotations

Segmentations were drawn in ITK-SNAP. One board-certified radiologist outlined the central gland and peripheral zone on T2w, and a second reviewed them. Both readers independently segmented PI-RADS 4 and 5 lesions on the ADC map, adjusted against T2w and DWI. Reader 1 also segmented lesions on T2w. The test cases carry anatomy and lesion labels from both readers.

Known limitations

  • Single center, single vendor and one field strength.
  • The data descriptor states an inclusion age over 50, yet reports a minimum age of 35.
  • Lesions below PI-RADS 4 are not segmented.
  • Resampling and cropping discard the original resolution of the DWI and ADC series.
  • The challenge page describes the test set as hidden, while a Zenodo record now offers it for download.

Cohort

Aggregate numbers from the sources below. Bars are relative to the 158 subjects.

Age

mean 69 ± 9, range 35 to 84

No age bins reported.

Characteristics of the Patient Cohort table in Adams et al. 2022, Data in Brief 45, 108739, Dataset of prostate MRI annotated for anatomical zones and cancer

Condition

Groups can overlap

  • Prostate cancer 102 65%

Specifications Table in Adams et al. 2022, Data in Brief 45, 108739, Dataset of prostate MRI annotated for anatomical zones and cancer

Split

  • Training 139 88%
  • Test 19 12%

Characteristics of the Patient Cohort table in Adams et al. 2022, Data in Brief 45, 108739, Dataset of prostate MRI annotated for anatomical zones and cancer

Contrast / sequence

Groups can overlap

  • T2-weighted 158 100%
  • Diffusion-weighted 158 100%
  • ADC map 158 100%

Abstract in Adams et al. 2022, Computers in Biology and Medicine 148, 105817 (abstract)

Split by condition

Reported cross table. A dot marks a cell the source does not give.

Prostate cancer
Training83
Test19

Characteristics of the Patient Cohort table in Adams et al. 2022, Data in Brief 45, 108739, Dataset of prostate MRI annotated for anatomical zones and cancer

Contrast combinations

How many subjects have exactly each set of contrasts.

T2wdwiADCSubjects with exactly this set
158

Abstract in Adams et al. 2022, Computers in Biology and Medicine 148, 105817 (abstract)

License and access

Our reading of the license, not legal advice. Before you use the data, read the original license and confirm that your use is allowed. We take no responsibility for how you use a dataset. Full disclaimer

Access
Open download

Download without an account

Access page

Prostate158 Research Use Agreement

Personal, non-commercial research use only. Each user registers and agrees individually. The data may not be passed on, modified or used to create derivative works, re-identification is forbidden, and the data must not be used for patient care.

The Research Use Agreement on the challenge data page applies to everyone who registers for downloads. The Zenodo records carry no license field, and on 2026-10-09 both zip files downloaded without an account.

Original license text Version read: Research Use Agreement on the Prostate158 challenge data page, read 2026-10-09 Checked 2026-10-09

What you can do

  • No
  • Not stated
  • Conditional
  • No
  • Not stated

What you can share

  • No
  • No
  • Not stated

What you must do

  • Not stated
  • Share alike No
  • Yes
  • No
  • Manuscript review No
  • Release code No
  • Return results No
  • Conditional

Limits

  • Yes
  • Location limits No

Citation

Adams LC, Makowski MR, Engel G, Rattunde M, Busch F, Asbach P, Niehues SM, Vinayahalingam S, van Ginneken B, Litjens G, Bressem KK. Prostate158 - An expert-annotated 3T MRI dataset and algorithm for prostate cancer detection. Computers in Biology and Medicine 148, 105817 (2022). doi:10.1016/j.compbiomed.2022.105817

Sources

Every number on this page comes from one of these documents. Each chart names the table or page it is taken from. The raw numbers are in stats.csv.